ES2381304T3 - Antígenos y anticuerpos novedosos asociados a adenocarcinoma ductal pancreático - Google Patents

Antígenos y anticuerpos novedosos asociados a adenocarcinoma ductal pancreático Download PDF

Info

Publication number
ES2381304T3
ES2381304T3 ES07820692T ES07820692T ES2381304T3 ES 2381304 T3 ES2381304 T3 ES 2381304T3 ES 07820692 T ES07820692 T ES 07820692T ES 07820692 T ES07820692 T ES 07820692T ES 2381304 T3 ES2381304 T3 ES 2381304T3
Authority
ES
Spain
Prior art keywords
pda
enoa
antibodies
isoforms
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07820692T
Other languages
English (en)
Spanish (es)
Inventor
Francesco Novelli
Barbara Tomaino
Paola Cappello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Original Assignee
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies SA, Bioline Diagnostici SRL filed Critical Ribovax Biotechnologies SA
Application granted granted Critical
Publication of ES2381304T3 publication Critical patent/ES2381304T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES07820692T 2006-09-29 2007-09-28 Antígenos y anticuerpos novedosos asociados a adenocarcinoma ductal pancreático Active ES2381304T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06121552 2006-09-29
EP06121552 2006-09-29
EP06126726 2006-12-20
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
ES2381304T3 true ES2381304T3 (es) 2012-05-25

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07820692T Active ES2381304T3 (es) 2006-09-29 2007-09-28 Antígenos y anticuerpos novedosos asociados a adenocarcinoma ductal pancreático

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171569A (zh) * 2008-05-09 2011-08-31 杜克大学 检测和治疗癌症的自身抗体
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
CA2949045C (en) * 2013-12-20 2022-07-05 Development Center For Biotechnology Alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3094341B1 (en) 2014-01-13 2019-10-02 Berg LLC Enolase 1 (eno1) compositions and uses thereof
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
AU2007301966A1 (en) 2008-04-03
PT2069395E (pt) 2012-04-27
EA200970332A1 (ru) 2009-10-30
EP2069395B1 (en) 2012-01-25
US20100028907A1 (en) 2010-02-04
JP2010505104A (ja) 2010-02-18
AU2007301966B2 (en) 2013-02-21
IL197868A (en) 2013-03-24
PL2069395T3 (pl) 2012-06-29
EA016731B1 (ru) 2012-07-30
DK2069395T3 (da) 2012-05-14
WO2008037792A1 (en) 2008-04-03
CN101578295B (zh) 2013-02-27
US8071721B2 (en) 2011-12-06
IL218442A0 (en) 2012-04-30
NZ576409A (en) 2012-02-24
CA2664841A1 (en) 2008-04-03
EP2069395A1 (en) 2009-06-17
BRPI0717282A2 (pt) 2013-10-15
ATE542831T1 (de) 2012-02-15
IL197868A0 (en) 2011-08-01
NO20091662L (no) 2009-06-29
CN101578295A (zh) 2009-11-11
KR20090094227A (ko) 2009-09-04

Similar Documents

Publication Publication Date Title
Wang et al. CPT 1A‐mediated succinylation of S100A10 increases human gastric cancer invasion
ES2745014T3 (es) Proteína
ES2381304T3 (es) Antígenos y anticuerpos novedosos asociados a adenocarcinoma ductal pancreático
Gomes et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions
Wang et al. An autoantigen atlas from human lung HFL1 cells offers clues to neurological and diverse autoimmune manifestations of COVID-19
Zhao et al. Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in breast carcinoma
Schröder et al. Molecular characterisation of ‘transmembrane protein 192’(TMEM192), a novel protein of the lysosomal membrane.
Lu et al. Benchmark of site-and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer
Aggelis et al. Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel‐Lindau transfectant cell line model
US9903872B2 (en) Identification of protein associated with hepatocellular carcinoma, gliobastoma and lung cancer
US20200369729A1 (en) Peptidomimetics, method of synthesis and uses thereof
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
WO2010071787A1 (en) Pancreatic cancer markers and uses thereof
JP7546255B2 (ja) 癌を検出する方法および検出試薬
WO2010071788A1 (en) Pancreatic cancer markers and uses thereof
Afshari et al. Glycoproteoforms of osteoarthritis-associated lubricin in plasma and synovial fluid
Noh et al. Comparative proteomic analyses of synovial fluids and serums from rheumatoid arthritis patients
Arielly et al. Quantitative analysis of caveolin-rich lipid raft proteins from primary and metastatic colorectal cancer clones
Mackay et al. Prostate‐specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma
Saar-Kovrov et al. Protein carbamylation in atherosclerotic plaques correlates with uremia and disease progression, localizing predominantly to foam cells
Ye et al. Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
ES2870698T3 (es) Uso de un agente de captura de fibrinógeno para detectar una variante b de Ciz1
San Francisco et al. Role of proteomics in the study of Trypanosoma cruzi biology
Hintze et al. The ligand preference of LRP1 is regulated by O-glycans
Ferreira et al. Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes